<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046643</url>
  </required_header>
  <id_info>
    <org_study_id>1R21AG031951-01A1</org_study_id>
    <secondary_id>1R21AG031951-01A1</secondary_id>
    <nct_id>NCT01046643</nct_id>
  </id_info>
  <brief_title>Early Menopause Hormone Treatment and Cognition</brief_title>
  <acronym>R21</acronym>
  <official_title>Hormones and Cognitive Processing in Early Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the neurobiological effects of hormone therapy
      (HT) in healthy early postmenopausal women. The studies proposed in this project seek to
      define the association between different hormone forms (estradiol only and progesterone only)
      versus placebo on brain functional measures. The functional measures will include the
      performance of the volunteers on a comprehensive neuropsychological testing battery, and the
      brain functional responses to episodic memory (verbal and non-verbal) challenges as well as
      emotional processing determined with functional magnetic resonance imaging (fMRI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims

      Aim 1. To examine the effects of estradiol alone on brain functioning in early
      post-menopausal women during verbal and non-verbal cognitive tasks.

      Hypothesis: It is expected that with estradiol treatment brain activation will be more
      prominent in the hippocampus and prefrontal cortical areas compared to placebo. The magnitude
      of activation in these regions will be positively correlated with task performance in the
      scanner and with the results of neuropsychological tests assessing verbal and non-verbal
      delayed recall.

      Aim 2. To determine the effects of progesterone alone on brain functioning in early
      postmenopausal women during verbal and non-verbal cognitive tasks.

      Hypothesis: It is expected that with progesterone treatment brain activation in the
      hippocampus and prefrontal cortical areas will be decreased compared to both the placebo
      condition (within subjects) and the estradiol condition (between subjects). Interindividual
      variations in the magnitude of activation in these regions will be positively correlated with
      task performance in the scanner and with the results of neuropsychological tests assessing
      verbal and non-verbal delayed recall.

      Aim 3. To determine the individual effects of estradiol and progesterone on brain functioning
      in early postmenopausal women during emotional processing stimuli.

      Hypothesis: During negative stimuli estradiol-treated women compared to placebo group, are
      expected to have increased activity in the amygdala, posterior cingulate, and orbitofrontal
      cortex, while in progesterone-treated women compared to placebo, decreased activity is
      expected in these brain regions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans</measure>
    <time_frame>August 2010 - March 2012</time_frame>
    <description>Measure the changes in brain activity in verbal tasks with hormone use (either estradiol or progesterone) versus placebo.
The test is a deep and shallow verbal processing task, where the subjects are presented lists of words, one word at a time, and are asked to make one of 2 decisions about each list. One decision is whether each word is written in upper or lower case letters (shallow processing), and the other decision is whether each word denotes an abstract or concrete concept (deep processing).
The test was administered 3 months after baseline and 38 weeks after baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Brain Activation Patterns in Visual Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans</measure>
    <time_frame>August 2010 - March 2012</time_frame>
    <description>Measure the changes in brain activity in visual tasks with hormone use (either estradiol or progesterone) versus placebo.
The test is a visual working memory task, where the women are presented with 3 geometric grids on the screen. The target grid is on top, and 2 test grids are on the bottom. The women must decide if the right or left test grid matches the grid on top. There are 3 conditions: a match condition where all 3 grids are shown simultaneously, and 2 delay conditions, where the target grid is shown first, disappears, and the test grids appear after a 1 or a 4 second delay.
The test was administered 3 months after baseline and 38 weeks after baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Testing Scores - Verbal Learning Retention</measure>
    <time_frame>August 2010 - March 2012</time_frame>
    <description>Changes in neuropsychological testing measures (verbal learning retention) with hormone use (either estradiol or progesterone) versus placebo.
Subjects are given tests that present them with a series of words. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the Benton Visual Memory Test, Revised.
The tests were administered 3 months after baseline and 38 weeks after baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Testing Scores - Visual Learning Retention</measure>
    <time_frame>August 2010 - March 2012</time_frame>
    <description>Changes in neuropsychological testing measures (visual learning retention) with hormone use (either estradiol or progesterone) versus placebo.
Subjects are given tests that present them with a series of pictures. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the California Verbal Learning Test - 2nd edition.
The tests were administered 3 months after baseline and 38 weeks after baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Menopausal Syndrome</condition>
  <arm_group>
    <arm_group_label>Estrogen followed by Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Estrogen treatment with Estradiol (E2) followed by Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone followed by Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Progesterone (P10) treatment followed by Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by Estrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo followed by Estrogen treatment with Estradiol (E2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by Progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo followed by Progesterone (P10) treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol (E2)</intervention_name>
    <description>One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.</description>
    <arm_group_label>Estrogen followed by Placebo</arm_group_label>
    <arm_group_label>Placebo followed by Estrogen</arm_group_label>
    <other_name>E2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone (P10) x90</intervention_name>
    <description>One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.</description>
    <arm_group_label>Progesterone followed by Placebo</arm_group_label>
    <arm_group_label>Placebo followed by Progesterone</arm_group_label>
    <other_name>P10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone (P10) x10</intervention_name>
    <description>One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.</description>
    <arm_group_label>Estrogen followed by Placebo</arm_group_label>
    <arm_group_label>Placebo followed by Estrogen</arm_group_label>
    <other_name>P10</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women

          -  Ages 45-55, 6 - 36 months from their last menstrual period.

        Exclusion Criteria:

          -  Left handedness

          -  Acute medical illness

          -  Neurologic illness

          -  Psychiatric illness

          -  Heart disease

          -  Thromboembolic disease

          -  Liver disease

          -  Uncorrected thyroid disease

          -  Diabetes

          -  Neurological disease

          -  Porphyria

          -  Allergy to estradiol

          -  Progesterone or lactose

          -  Lactose intolerance

          -  Claustrophobia

          -  Contraindications to MRI (including pacemakers, surgical clips or metallic surgical
             devices)

          -  Smoking within the last 3 years

          -  Use of hormones within the last 3 months

          -  Current or past history of substance abuse

          -  History of head injury or loss of consciousness

          -  Medications with actions on the central nervous system

          -  Endometrial lining greater than 5mm

          -  Ovarian pathology on ultrasound

          -  Abnormal mammogram

          -  Migraines

          -  Fasting cholesterol &gt;300 mg/dl, and fasting triglycerides &gt;300 mg/dl

          -  Creatinine level &gt; 1.5 mg/dl

          -  Aspartate transaminase (AST) or Alanine transaminase (ALT) greater than two times the
             top normal range

          -  Follicle stimulating hormone (FSH) values &lt;40 IU/L

          -  estradiol &gt;40 pg/ml.

          -  Subjects with HAM-D score &gt; 8, HAM-A &gt; 6 during screening will not be eligible.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yolanda R. Smith, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <results_first_submitted>February 2, 2013</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Yolanda Smith, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>Healthy</keyword>
  <keyword>Menopausal</keyword>
  <keyword>Hormone treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>+++__Women were recruited from 3/1/2010 to 7/29/2011 through local newspaper ads, flyers, electronic newsletters, bulletin boards, clinics and the Women’s Health Registry, a University of Michigan database of women interested in participating in women’s health related clinical research.</recruitment_details>
      <pre_assignment_details>Several enrolled participants were excluded from the trial prior to assignment in groups on the basis of the risk factors identified at the pre-screening appointment. Some others did not qualify due to their lab results which did not meet the inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Estrogen Followed by Placebo</title>
          <description>Estrogen treatment with Estradiol (E2)
One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days followed by one Placebo capsule once per day for 90 days, at the same time each day</description>
        </group>
        <group group_id="P2">
          <title>Progesterone Followed by Placebo</title>
          <description>Progesterone (P10) treatment
One Progesterone (P10) (200 mg) capsule once a day, at the same time each day, for 90 days, followed by one Placebo capsule once per day for 90 days, at the same time each day.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Followed by Estrogen</title>
          <description>One Placebo capsule once per day for 90 days, at the same time each day, followed by one Estradiol capsule (E2) (1mg) once a day, at the same time each day, for 90 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Followed by Progesterone</title>
          <description>One Placebo capsule once per day for 90 days, at the same time each day, followed by one Progesterone (P10) (200 mg) capsule once a day, at the same time each day, for 90 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Period Treatment or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Period Treatment or Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Estrogen and Placebo</title>
          <description>Estrogen treatment with Estradiol (E2)
Participants received both an Estradiol capsule (E2) (1mg) and a Placebo capsule in a randomized sequence (for a total of two sequences of 90 days each, consisting of one capsule, once per day at the same time each day).</description>
        </group>
        <group group_id="B2">
          <title>Progesterone and Placebo</title>
          <description>Progesterone treatment (P10)
Participants received both a Progesterone capsule (P10) (200 mg) and a Placebo capsule in a randomized sequence (for a total of two sequences of 90 days each, consisting of one capsule, once per day at the same time each day).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="2.2"/>
                    <measurement group_id="B2" value="51.2" spread="2.9"/>
                    <measurement group_id="B3" value="51.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Months since Last Menstrual Period</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.81" spread="9.57"/>
                    <measurement group_id="B2" value="16.69" spread="9.80"/>
                    <measurement group_id="B3" value="18.41" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.75" spread="2.82"/>
                    <measurement group_id="B2" value="17.19" spread="2.67"/>
                    <measurement group_id="B3" value="16.4" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estradiol</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.75" spread="6.30"/>
                    <measurement group_id="B2" value="14.38" spread="6.25"/>
                    <measurement group_id="B3" value="16.24" spread="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Follicle-Stimulating Hormone</title>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.34" spread="33.85"/>
                    <measurement group_id="B2" value="80.86" spread="21.60"/>
                    <measurement group_id="B3" value="87.19" spread="29.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.13" spread="6.13"/>
                    <measurement group_id="B2" value="28.38" spread="3.8"/>
                    <measurement group_id="B3" value="27.69" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans</title>
        <description>Measure the changes in brain activity in verbal tasks with hormone use (either estradiol or progesterone) versus placebo.
The test is a deep and shallow verbal processing task, where the subjects are presented lists of words, one word at a time, and are asked to make one of 2 decisions about each list. One decision is whether each word is written in upper or lower case letters (shallow processing), and the other decision is whether each word denotes an abstract or concrete concept (deep processing).
The test was administered 3 months after baseline and 38 weeks after baseline.</description>
        <time_frame>August 2010 - March 2012</time_frame>
        <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged and unable to be used in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Estrogen</title>
            <description>Estrogen treatment with Estradiol (E2)
Estradiol (E2) : One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>Progesterone treatment
Progesterone (P10) : One Progesterone (200 mg) capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Estrogen)</title>
            <description>Placebo phase of Estradiol (E2) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Progesterone)</title>
            <description>Placebo phase of Progesterone (P10) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans</title>
          <description>Measure the changes in brain activity in verbal tasks with hormone use (either estradiol or progesterone) versus placebo.
The test is a deep and shallow verbal processing task, where the subjects are presented lists of words, one word at a time, and are asked to make one of 2 decisions about each list. One decision is whether each word is written in upper or lower case letters (shallow processing), and the other decision is whether each word denotes an abstract or concrete concept (deep processing).
The test was administered 3 months after baseline and 38 weeks after baseline.</description>
          <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged and unable to be used in the analysis.</population>
          <units>percent BOLD signal changes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medial Frontal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".14" spread=".12"/>
                    <measurement group_id="O2" value=".13" spread=".16"/>
                    <measurement group_id="O3" value=".05" spread="021"/>
                    <measurement group_id="O4" value=".13" spread=".18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.04" spread=".14"/>
                    <measurement group_id="O2" value="-.01" spread=".15"/>
                    <measurement group_id="O3" value="-.13" spread=".16"/>
                    <measurement group_id="O4" value=".09" spread=".34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.06" spread=".18"/>
                    <measurement group_id="O2" value="-.06" spread=".13"/>
                    <measurement group_id="O3" value="-.14" spread=".16"/>
                    <measurement group_id="O4" value=".01" spread=".24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Category = Medial Frontal Cortex
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.222</p_value>
            <p_value_desc>Category = Medial Frontal Cortex</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Category = Left Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.107</p_value>
            <p_value_desc>Category = Left Hippocampus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Category = Right Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.127</p_value>
            <p_value_desc>Category = Medial Frontal Cortex</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Category = Medial Frontal Cortex
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.954</p_value>
            <p_value_desc>Category = Medial Frontal Cortex</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Category = Left Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.385</p_value>
            <p_value_desc>Category = Left Hippocampus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Category = Right Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.310</p_value>
            <p_value_desc>Category = Right Hippocampus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Testing Scores - Verbal Learning Retention</title>
        <description>Changes in neuropsychological testing measures (verbal learning retention) with hormone use (either estradiol or progesterone) versus placebo.
Subjects are given tests that present them with a series of words. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the Benton Visual Memory Test, Revised.
The tests were administered 3 months after baseline and 38 weeks after baseline.</description>
        <time_frame>August 2010 - March 2012</time_frame>
        <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged.</population>
        <group_list>
          <group group_id="O1">
            <title>Estrogen</title>
            <description>Estrogen treatment with Estradiol (E2)
Estradiol (E2) : One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>Progesterone treatment
Progesterone (P10) : One Progesterone (200 mg) capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Estrogen)</title>
            <description>Placebo phase of Estradiol (E2) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Progesterone)</title>
            <description>Placebo phase of Progesterone (P10) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Testing Scores - Verbal Learning Retention</title>
          <description>Changes in neuropsychological testing measures (verbal learning retention) with hormone use (either estradiol or progesterone) versus placebo.
Subjects are given tests that present them with a series of words. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the Benton Visual Memory Test, Revised.
The tests were administered 3 months after baseline and 38 weeks after baseline.</description>
          <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged.</population>
          <units>percent retention</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.79" spread="6.72"/>
                    <measurement group_id="O2" value="97.12" spread="15.30"/>
                    <measurement group_id="O3" value="94.94" spread="10.75"/>
                    <measurement group_id="O4" value="98.44" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.594</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.653</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Brain Activation Patterns in Visual Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans</title>
        <description>Measure the changes in brain activity in visual tasks with hormone use (either estradiol or progesterone) versus placebo.
The test is a visual working memory task, where the women are presented with 3 geometric grids on the screen. The target grid is on top, and 2 test grids are on the bottom. The women must decide if the right or left test grid matches the grid on top. There are 3 conditions: a match condition where all 3 grids are shown simultaneously, and 2 delay conditions, where the target grid is shown first, disappears, and the test grids appear after a 1 or a 4 second delay.
The test was administered 3 months after baseline and 38 weeks after baseline.</description>
        <time_frame>August 2010 - March 2012</time_frame>
        <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged.</population>
        <group_list>
          <group group_id="O1">
            <title>Estrogen</title>
            <description>Estrogen treatment with Estradiol (E2)
Estradiol (E2) : One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>Progesterone treatment
Progesterone (P10) : One Progesterone (200 mg) capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Estrogen)</title>
            <description>Placebo phase of Estradiol (E2) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Progesterone)</title>
            <description>Placebo phase of Progesterone (P10) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Brain Activation Patterns in Visual Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans</title>
          <description>Measure the changes in brain activity in visual tasks with hormone use (either estradiol or progesterone) versus placebo.
The test is a visual working memory task, where the women are presented with 3 geometric grids on the screen. The target grid is on top, and 2 test grids are on the bottom. The women must decide if the right or left test grid matches the grid on top. There are 3 conditions: a match condition where all 3 grids are shown simultaneously, and 2 delay conditions, where the target grid is shown first, disappears, and the test grids appear after a 1 or a 4 second delay.
The test was administered 3 months after baseline and 38 weeks after baseline.</description>
          <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged.</population>
          <units>percent BOLD signal changes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medial Frontal Cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".25" spread=".17"/>
                    <measurement group_id="O2" value=".47" spread=".28"/>
                    <measurement group_id="O3" value=".16" spread=".41"/>
                    <measurement group_id="O4" value=".20" spread=".43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".21" spread=".20"/>
                    <measurement group_id="O2" value=".38" spread=".25"/>
                    <measurement group_id="O3" value=".23" spread=".38"/>
                    <measurement group_id="O4" value=".21" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Hippocampus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".29" spread=".17"/>
                    <measurement group_id="O2" value=".38" spread=".29"/>
                    <measurement group_id="O3" value=".21" spread=".48"/>
                    <measurement group_id="O4" value=".15" spread=".29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Category = Medial Frontal Cortex
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.452</p_value>
            <p_value_desc>Category = Medial Frontal Cortex</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Category = Left Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.868</p_value>
            <p_value_desc>Category = Left Hippocampus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Category = Right Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.549</p_value>
            <p_value_desc>Category = Right Hippocampus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Category = Medial Frontal Cortex
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.124</p_value>
            <p_value_desc>Category = Medial Frontal Cortex</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Category = Left Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.158</p_value>
            <p_value_desc>Category = Left Hippocampus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Category = Right Hippocampus
p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.055</p_value>
            <p_value_desc>Category = Right Hippocampus</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Testing Scores - Visual Learning Retention</title>
        <description>Changes in neuropsychological testing measures (visual learning retention) with hormone use (either estradiol or progesterone) versus placebo.
Subjects are given tests that present them with a series of pictures. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the California Verbal Learning Test - 2nd edition.
The tests were administered 3 months after baseline and 38 weeks after baseline.</description>
        <time_frame>August 2010 - March 2012</time_frame>
        <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged.</population>
        <group_list>
          <group group_id="O1">
            <title>Estrogen</title>
            <description>Estrogen treatment with Estradiol (E2)
Estradiol (E2) : One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O2">
            <title>Progesterone</title>
            <description>Progesterone treatment
Progesterone (P10) : One Progesterone (200 mg) capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Estrogen)</title>
            <description>Placebo phase of Estradiol (E2) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Progesterone)</title>
            <description>Placebo phase of Progesterone (P10) treatment
One Placebo capsule once a day, at the same time each day, for 90 days</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Testing Scores - Visual Learning Retention</title>
          <description>Changes in neuropsychological testing measures (visual learning retention) with hormone use (either estradiol or progesterone) versus placebo.
Subjects are given tests that present them with a series of pictures. They are asked to recall how many items they can remember, and then some time later, are asked to recall the items again. The retention measure is how many items they can remember at the later time point, compared to the earlier time point. Adapted from the California Verbal Learning Test - 2nd edition.
The tests were administered 3 months after baseline and 38 weeks after baseline.</description>
          <population>Within the Estrogen/Placebo groups, 3 participants were unable to complete the needed fMRI analyses due to adverse events, and in the Progesterone/Placebo groups, 1 participant's fMRI scans were damaged.</population>
          <units>percent retention</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.31" spread="19.22"/>
                    <measurement group_id="O2" value="97.59" spread="13.67"/>
                    <measurement group_id="O3" value="97.01" spread="14.79"/>
                    <measurement group_id="O4" value="96.19" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.561</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>p-value for null hypothesis = &lt;0.05</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.726</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Estrogen Followed by Placebo</title>
          <description>Estrogen treatment with Estradiol (E2)
One Estradiol capsule (E2) (1mg) once a day, at the same time each day, for 90 days followed by one Placebo capsule once per day for 90 days, at the same time each day.</description>
        </group>
        <group group_id="E2">
          <title>Progesterone Followed by Placebo</title>
          <description>Progesterone treatment
One Progesterone (P10) (200 mg) capsule once a day, at the same time each day, for 90 days, followed by one Placebo capsule once per day for 90 days, at the same time each day.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Followed by Estrogen</title>
          <description>One Placebo capsule once per day for 90 days, at the same time each day, followed by one Estradiol capsule (E2) (1mg) capsule once a day, at the same time each day, for 90 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Followed by Progesterone</title>
          <description>One Placebo capsule once per day for 90 days, at the same time each day, followed by one Progesterone (P10) (200 mg) capsule once a day, at the same time each day, for 90 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Claustrophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Side effects of hormone use</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yolanda Smith</name_or_title>
      <organization>The University of Michigan</organization>
      <phone>(734) 936-7401</phone>
      <email>ysmith@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

